Skip to content
  • Research
  • Insights
  • Testimonials
  • Blog
  • White Papers
  • About
  • Contact Us
Menu
  • Research
  • Insights
  • Testimonials
  • Blog
  • White Papers
  • About
  • Contact Us
  • Research
  • Insights
  • Testimonials
  • Blog
  • White Papers
  • About
  • Contact Us
Menu
  • Research
  • Insights
  • Testimonials
  • Blog
  • White Papers
  • About
  • Contact Us

FDA Expands Transparency, Disclosure of KOL Involvement, Mirroring Pharma Trend

  • May 5, 2010

A recent Pharmaceutical Executive article outlined new US Food and Drug Administration draft guidance that would “expand transparency and disclosure when the agency grants a conflict of interest waiver to permit an individual’s participation at an FDA advisory committee meeting.”

The FDA, much like the many public and private companies that make up the biopharmaceutical industry, relies on the expertise and advice of research scientists and health care professionals as resources for policy-making that affects the public health of the United States.  The draft guidance seeks to implement new guidelines for identifying potential conflicts of interest among the scientists and physicians drafted to help form wide-ranging policy throughout the health care industry.

The FDA’s self-policing initiative mirrors the ongoing trend in the biopharmaceutical industry for greater ethics and transparency.  Pharmaceutical companies are embracing greater disclosure of their activities with thought leaders in the medical community, and they are turning to companies like Thought Leader Select for targeted advice on a variety of fronts where they engage thought leaders. Thought Leader Select’s advisory services span a variety of KOL development areas, including help with advisory boards, conferences, regulatory approval, clinical research, and many other aspects of the development of new medicines.

Thought Leader Select provides an unbiased, third-party perspective that proves vital to evolving pharmaceutical development needs through intensive documentation of the skills and experience of researchers and physicians.  In addition to company’s industry-leading research methodology, Thought Leader Select can develop engagement plans between companies and thought leaders to ensure compliance and transparency with all ethical policies.

Read the full Pharmaceutical Executive article here.

More Posts

TLS VP, Castle, Earns Elite DEI Certification

Thought Leader Select’s Vice President of Marketing & Strategy, Brian Castle has earned certification at the highest level for professionals and executives in the practice

Schoeman Named General Manager of Clear Point Health

Thought Leader Select has announced another leadership appointment, as Mark Schoeman has been named General Manager of the company’s Clear Point Health division. Clear Point

TLS Names Meade, Hanson, and Nufire to Research Leadership Positions

After closing out a prolific 2022, Thought Leaders Select is proud to announce a trio of colleagues taking on leadership roles with the company’s research

How is the Role of a Thought Leader in Healthcare Changing?

By Paul Meade, Patient Engagement Lead For many decades, the healthcare thought Leader, also known as a key opinion leader (KOL), or key external expert

Share:

Send Us A Message

  • Research
  • Insights
  • Testimonials
  • Blog
  • White Papers
  • About
  • Contact Us
Menu
  • Research
  • Insights
  • Testimonials
  • Blog
  • White Papers
  • About
  • Contact Us
logo-2020-300.png

1589 W. 5th Street
Washington, NC 27889
email

© 2021 All rights Reserved. THOUGHT LEADER SELECT

Facebook-f Twitter Linkedin